cebranopadol
Small moleculeexperimental
Cebranopadol is an investigational analgesic currently under development internationally by Tris Pharma, a private pharmaceutical company in the United States. The drug was originally discovered and developed by Grünenthal, a German pharmaceutical company and was formerly developed by Park Therapeutics and Depomed, pharmaceutical companies in the United States, for the treatment of a variety of different acute and chronic pain states. As of June 2025, phase III clinical trials have been completed for acute pain with positive results. — Wikipedia
Clinical trial activity
14 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
9
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00872885)
Timeline
Indications
Studied for
- Chronic Pain · Phase 3
- Diabetes Mellitus · Phase 2
- Diabetic Neuropathies · Phase 2
- Heart · Phase 1
- Low Back Pain · Phase 2
- Neoplasms · Phase 3
- Osteoarthritis, Knee · Phase 2
- Pain · Phase 3
- Pharmacokinetics · Phase 1
- Postoperative Pain · Phase 2
- Substance Abuse, Oral · Phase 1
- Substance-Related Disorders · Phase 1
Mechanism of action
- Nociceptin receptorAGONIST
OPRL1 agonist
Opioid receptors; mu/kappa/delta agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12- Mol. weight
- 378.49 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCebranopadol ↗
- ChEMBLCHEMBL2364605 ↗
Also known as
- 6'-fluoro-4',9'-dihydro-n,n-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'h)-pyrano(3,4-b)indol)-4-amine
- cebranopadol
- cebranopadol
- cebranopadol
- cebranopadol
- cebranopadol
- grt6005
- grt6005
- grt6005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05491785 | Phase 1 | Jul 29, 2022 | Leiden University, Tris Pharma, Inc. |
| NCT05256108 | Phase 1 | Mar 28, 2022 | Tris Pharma, Inc. |
| NCT02031432 | Phase 3 | Dec 1, 2013 | Grunenthal |
| NCT01964378 | Phase 3 | Nov 1, 2013 | Grunenthal |
| NCT01939366 | Phase 2 | Sep 1, 2013 | Forest Laboratories, Grunenthal |
| NCT03958123 | Phase 1 | Jul 10, 2013 | Forest Laboratories, Grunenthal |
| NCT03882762 | Phase 1 | Jun 20, 2013 | Forest Laboratories, Grunenthal |
| NCT03757559 | Phase 1 | Apr 15, 2013 | Grunenthal |
| NCT01709214 | Phase 2 | Nov 1, 2012 | Grunenthal |
| NCT01725087 | Phase 2 | Nov 1, 2012 | Forest Laboratories, Grunenthal |
| NCT01357837 | Phase 2 | May 1, 2011 | Forest Laboratories, Grunenthal, Specjalistyczne Centrum Medyczne, NOWOMED |
| NCT01347671 | Phase 2 | May 1, 2011 | Forest Laboratories, Grunenthal, ikfe GmbH |
| NCT00878293 | Phase 2 | Apr 1, 2009 | Grunenthal, Johannes Gutenburg University |
| NCT00872885 | Phase 2 | Mar 1, 2009 | Grunenthal |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grunenthal | For profit | 12 | 12 | 3 | 2009 |
| Forest Laboratories | For profit | 6 | 0 | 2 | 2011 |
| Tris Pharma, Inc. | For profit | 2 | 2 | 1 | 2022 |
| ikfe GmbH | For profit | 1 | 0 | 1 | 2011 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Specjalistyczne Centrum Medyczne, NOWOMED | Academic/Hospital | 1 | 0 | 1 | 2011 |
7 organizations
Page 1 / 1